|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
ATE538794T1
(de)
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
ATE419239T1
(de)
|
2000-10-20 |
2009-01-15 |
Eisai R&D Man Co Ltd |
Verfahren zur herstellung von 4-phenoxy chinolin derivaten
|
|
ATE345130T1
(de)
†
|
2001-12-03 |
2006-12-15 |
Bayer Pharmaceuticals Corp |
Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
|
|
US7838541B2
(en)
|
2002-02-11 |
2010-11-23 |
Bayer Healthcare, Llc |
Aryl ureas with angiogenesis inhibiting activity
|
|
US8299108B2
(en)
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
|
US7071216B2
(en)
|
2002-03-29 |
2006-07-04 |
Chiron Corporation |
Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
|
|
DE60304718T2
(de)
|
2002-08-06 |
2007-04-26 |
Astrazeneca Ab |
Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
|
|
WO2004020434A1
(ja)
*
|
2002-08-30 |
2004-03-11 |
Eisai Co., Ltd. |
含窒素芳香環誘導体
|
|
US7365209B2
(en)
|
2003-02-11 |
2008-04-29 |
Pharmacopeia, Inc. |
Nitrogen heterocycle biaryls for osteoporosis and other diseases
|
|
US7531553B2
(en)
*
|
2003-03-21 |
2009-05-12 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
ES2423800T3
(es)
|
2003-03-28 |
2013-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Uso de compuestos orgánicos para la inmunopotenciación
|
|
EP1611128A2
(en)
*
|
2003-03-28 |
2006-01-04 |
Pharmacia & Upjohn Company LLC |
Positive allosteric modulators of the nicotinic acetylcholine receptor
|
|
WO2004113274A2
(en)
|
2003-05-20 |
2004-12-29 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas with kinase inhibiting activity
|
|
US6887798B2
(en)
|
2003-05-30 |
2005-05-03 |
International Business Machines Corporation |
STI stress modification by nitrogen plasma treatment for improving performance in small width devices
|
|
CA2531859C
(en)
*
|
2003-07-11 |
2013-08-06 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Benzimidazole derivatives as raf kinase inhibitors
|
|
RS52625B
(sr)
|
2003-07-23 |
2013-06-28 |
Bayer Healthcare Llc |
Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
|
|
DE10334663A1
(de)
*
|
2003-07-30 |
2005-03-10 |
Merck Patent Gmbh |
Harnstoffderivate
|
|
DE10337942A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Merck Patent Gmbh |
Aminobenzimidazolderivate
|
|
DE10342503A1
(de)
|
2003-09-12 |
2005-04-14 |
Merck Patent Gmbh |
Benzyl-Benzimidazolylderivate
|
|
DE10344223A1
(de)
|
2003-09-24 |
2005-04-21 |
Merck Patent Gmbh |
1,3-Benzoxazolylderivate als Kinase-Inhibitoren
|
|
DE602004021838D1
(de)
|
2003-10-16 |
2009-08-13 |
Novartis Vaccines & Diagnostic |
Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
|
|
DE10349587A1
(de)
*
|
2003-10-24 |
2005-05-25 |
Merck Patent Gmbh |
Benzimidazolylderivate
|
|
CN101337930B
(zh)
|
2003-11-11 |
2010-09-08 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
|
CA2545711A1
(en)
*
|
2003-11-13 |
2005-06-02 |
Ambit Biosciences Corporation |
Urea derivatives as kinase modulators
|
|
DE10352979A1
(de)
*
|
2003-11-13 |
2005-06-09 |
Merck Patent Gmbh |
Pyridopyrimidinone
|
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
|
CA2557398A1
(en)
*
|
2004-02-26 |
2005-09-09 |
Hans-Peter Buchstaller |
Benzimidazolyl derivatives as kinase inhibitors
|
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
TW200538453A
(en)
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
|
ATE517885T1
(de)
|
2004-04-30 |
2011-08-15 |
Bayer Healthcare Llc |
Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
|
|
US7432373B2
(en)
|
2004-06-28 |
2008-10-07 |
Bristol-Meyers Squibb Company |
Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
|
|
US7439246B2
(en)
|
2004-06-28 |
2008-10-21 |
Bristol-Myers Squibb Company |
Fused heterocyclic kinase inhibitors
|
|
US7173031B2
(en)
|
2004-06-28 |
2007-02-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
US20090181092A1
(en)
*
|
2004-07-16 |
2009-07-16 |
Spinal Restoration, Inc. |
Methods for Treating Joints and Discs with a Carrier Matrix and Cells
|
|
JP4834553B2
(ja)
|
2004-09-17 |
2011-12-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
医薬組成物
|
|
JP4789180B2
(ja)
*
|
2004-09-28 |
2011-10-12 |
第一三共株式会社 |
６−置換−１−メチル−１−ｈ−ベンズイミダゾール誘導体の製造方法及びその製造中間体
|
|
US7816552B2
(en)
|
2004-09-28 |
2010-10-19 |
Sankyo Company, Limited |
Intermediate of 6-substituted 1-methyl-1-H-benzimidazole derivative and method for producing same
|
|
DE502005002697D1
(de)
*
|
2004-10-13 |
2008-03-13 |
Merck Patent Gmbh |
Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs
|
|
JP5089392B2
(ja)
*
|
2004-10-13 |
2012-12-05 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
キナーゼ阻害剤としての複素環式置換ビスアリール尿素誘導体
|
|
GB0423554D0
(en)
*
|
2004-10-22 |
2004-11-24 |
Cancer Rec Tech Ltd |
Therapeutic compounds
|
|
DE102004054216A1
(de)
|
2004-11-10 |
2006-05-11 |
Merck Patent Gmbh |
Substituierte 4-Amino-pyridopyrimidinone
|
|
EP1674466A1
(en)
*
|
2004-12-27 |
2006-06-28 |
4Sc Ag |
2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
|
|
US7576090B2
(en)
|
2004-12-27 |
2009-08-18 |
4Sc Ag |
Benzazole analogues and uses thereof
|
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
|
US7202513B1
(en)
|
2005-09-29 |
2007-04-10 |
International Business Machines Corporation |
Stress engineering using dual pad nitride with selective SOI device architecture
|
|
US8926945B2
(en)
|
2005-10-07 |
2015-01-06 |
Guerbet |
Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
|
|
US8986650B2
(en)
|
2005-10-07 |
2015-03-24 |
Guerbet |
Complex folate-NOTA-Ga68
|
|
PL2010528T3
(pl)
|
2006-04-19 |
2018-03-30 |
Novartis Ag |
6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
|
|
US7951819B2
(en)
|
2006-04-26 |
2011-05-31 |
Cancer Research Technology Limited |
Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
|
|
EA200802058A1
(ru)
|
2006-05-09 |
2009-06-30 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и их фармацевтические композиции
|
|
RU2448708C3
(ru)
|
2006-05-18 |
2017-09-28 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое средство против рака щитовидной железы
|
|
US8865737B2
(en)
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
|
JP2010504362A
(ja)
*
|
2006-09-25 |
2010-02-12 |
アレテ セラピューティクス， インコーポレイテッド |
可溶性エポキシドヒドロラーゼ阻害剤
|
|
BRPI0717288A2
(pt)
*
|
2006-09-28 |
2013-10-15 |
Arete Therapeutics Inc |
Inibidores de epóxido hidrolase solúvel
|
|
WO2008093855A1
(ja)
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
未分化型胃癌治療用組成物
|
|
CA2689514C
(en)
|
2007-06-05 |
2015-09-29 |
Takeda Pharmaceutical Company Limited |
Heterobicyclic compounds as kinase inhibitors
|
|
BRPI0815503A2
(pt)
*
|
2007-08-17 |
2014-09-30 |
Icagen Inc |
Composto, composição farmacêutica, e, métodos para modular a atividade de um canal de íon potássio em um indivíduo, para aumentar o fluxo de íon por meio de canais de potássio dependentes da voltagem em uma célula e para tratar, prevenir, inibir ou aliviar um distúrbio ou condição do sistema nervoso central ou periférico
|
|
US8431608B2
(en)
|
2007-08-17 |
2013-04-30 |
Icagen Inc. |
Heterocycles as potassium channel modulators
|
|
JP5270553B2
(ja)
*
|
2007-08-23 |
2013-08-21 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
|
JP5350247B2
(ja)
*
|
2007-08-29 |
2013-11-27 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
|
KR101513326B1
(ko)
|
2007-11-09 |
2015-04-17 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 신생 저해 물질과 항종양성 백금 착물의 병용
|
|
UA105763C2
(uk)
*
|
2007-12-19 |
2014-06-25 |
Кансер Рісерч Текнолоджі Лімітед |
8-ЗАМІЩЕНІ ПІРИДО[2,3-b]ПІРАЗИНИ ТА ЇХ ЗАСТОСУВАННЯ
|
|
EP2444403A1
(en)
|
2008-04-18 |
2012-04-25 |
Shionogi Co., Ltd. |
Heterocyclic compound having inhibitory activity on PI3K
|
|
GB0807609D0
(en)
*
|
2008-04-25 |
2008-06-04 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
US8445509B2
(en)
|
2008-05-08 |
2013-05-21 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic derivatives and use thereof
|
|
EP2307456B1
(en)
|
2008-06-27 |
2014-10-15 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
|
EP2399921B1
(en)
|
2008-12-01 |
2015-08-12 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
|
FR2942227B1
(fr)
|
2009-02-13 |
2011-04-15 |
Guerbet Sa |
Utilisation de tampons pour la complexation de radionucleides
|
|
WO2010126922A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Glaxosmithkline Llc |
Benzimidazolecarboxamides as inhibitors of fak
|
|
TH121482A
(th)
|
2009-08-19 |
2013-02-28 |
นางสาวปัณณพัฒน์ เหลืองธาตุทอง |
องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
|
|
NZ706154A
(en)
|
2010-02-01 |
2016-09-30 |
Cancer Rec Tech Ltd |
1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
|
|
KR101837759B1
(ko)
|
2010-02-18 |
2018-04-26 |
브이티브이 테라퓨틱스 엘엘씨 |
치환된 융합 이미다졸 유도체, 약학적 조성물, 및 그것의 사용 방법
|
|
US8759535B2
(en)
|
2010-02-18 |
2014-06-24 |
High Point Pharmaceuticals, Llc |
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
|
|
AU2011270165B2
(en)
|
2010-06-25 |
2015-12-24 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
|
WO2012031196A1
(en)
|
2010-09-03 |
2012-03-08 |
Forma Therapeutics, Inc. |
4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer
|
|
FR2968999B1
(fr)
|
2010-12-20 |
2013-01-04 |
Guerbet Sa |
Nanoemulsion de chelate pour irm
|
|
WO2012144463A1
(ja)
|
2011-04-18 |
2012-10-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
FR2980364B1
(fr)
|
2011-09-26 |
2018-08-31 |
Guerbet |
Nanoemulsions et leur utilisation comme agents de contraste
|
|
RU2015115397A
(ru)
|
2012-12-21 |
2017-01-25 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Аморфная форма производного хинолина и способ его получения
|
|
FR3001154B1
(fr)
|
2013-01-23 |
2015-06-26 |
Guerbet Sa |
Magneto-emulsion vectorisee
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
ES2687968T3
(es)
|
2013-05-14 |
2018-10-30 |
Eisai R&D Management Co., Ltd. |
Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
|
|
US9988386B2
(en)
*
|
2013-05-30 |
2018-06-05 |
Kata Pharmaceuticals, Inc. |
Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof
|
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
GB201320732D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Methods of chemical synthesis
|
|
KR20230043234A
(ko)
|
2014-08-28 |
2023-03-30 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
고순도의 퀴놀린 유도체 및 이를 제조하는 방법
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
WO2016089648A1
(en)
|
2014-12-01 |
2016-06-09 |
Vtv Therapeutics Llc |
Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
|
|
LT3263106T
(lt)
|
2015-02-25 |
2024-01-10 |
Eisai R&D Management Co., Ltd. |
Chinolino darinių kartumo sumažinimo būdas
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
MX373231B
(es)
|
2015-06-16 |
2020-05-08 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
|
CA2994925C
(en)
|
2015-08-20 |
2023-08-29 |
Eisai R&D Management Co., Ltd. |
Tumor therapeutic agent
|
|
CA3043549C
(en)
*
|
2015-11-30 |
2023-11-21 |
Children's Medical Center Corporation |
Compounds for treating proliferative diseases
|
|
WO2018051306A1
(en)
|
2016-09-19 |
2018-03-22 |
Novartis Ag |
Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
KR20240032157A
(ko)
|
2017-05-02 |
2024-03-08 |
노파르티스 아게 |
병용 요법
|
|
BR112019023064A2
(pt)
|
2017-05-16 |
2020-06-09 |
Eisai R&D Man Co Ltd |
tratamento de carcinoma hepatocelular
|
|
CN107954939B
(zh)
*
|
2017-12-07 |
2019-09-17 |
福建医科大学 |
一种微波辐射下n,n-二甲基氨基硫代甲酰氯衍生物催化合成苯并咪唑衍生物的方法
|
|
WO2020097400A1
(en)
|
2018-11-07 |
2020-05-14 |
Dana-Farber Cancer Institute, Inc. |
Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
|
|
US12415816B2
(en)
|
2018-11-07 |
2025-09-16 |
Dana-Farber Cancer Institute, Inc. |
Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
|
|
US12522583B2
(en)
|
2018-11-07 |
2026-01-13 |
Dana-Farber Cancer Institute, Inc. |
Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
|
|
EP3946618A1
(en)
*
|
2019-04-05 |
2022-02-09 |
Storm Therapeutics Ltd |
Mettl3 inhibitory compounds
|
|
MX2021013817A
(es)
|
2019-05-13 |
2021-12-14 |
Novartis Ag |
Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
|
|
TW202204350A
(zh)
|
2020-05-06 |
2022-02-01 |
美商雅捷可斯治療公司 |
作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
|
|
CN116348114B
(zh)
*
|
2020-10-19 |
2025-09-16 |
高丽大学校产学协力团 |
硫代苯并咪唑衍生物或其药学上可接受的盐及其用途
|
|
US12043632B2
(en)
|
2020-12-23 |
2024-07-23 |
Ajax Therapeutics, Inc. |
6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
|
|
WO2023086320A1
(en)
|
2021-11-09 |
2023-05-19 |
Ajax Therapeutics, Inc. |
Forms and compositions of inhibitors of jak2
|
|
CA3234638A1
(en)
|
2021-11-09 |
2023-05-19 |
Ajax Therapeutics, Inc. |
6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
|
|
TW202346485A
(zh)
|
2022-03-28 |
2023-12-01 |
瑞士商杭斯曼高級材料公司 |
基於2-羥基萘-3-羧酸的分散偶氮染料
|
|
CN115724837B
(zh)
*
|
2022-10-26 |
2024-07-23 |
中国人民解放军海军军医大学 |
一种抑制程序性细胞坏死的苯并噻唑衍生物及其应用
|
|
CN117820253A
(zh)
*
|
2023-09-19 |
2024-04-05 |
西北农林科技大学 |
3,6-二取代苯并噻唑类化合物及其合成与应用
|